Cilostazol reduces Angiographic Restenosis after Endovascular Therapy for Femoropopliteal Lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study
نویسندگان
چکیده
Osamu Iida, MD; Hiroyoshi Yokoi, MD; Yoshimitsu Soga, MD; Naoto Inoue, MD; Kenji Suzuki, MD; Yoshiaki Yokoi, MD, PhD; Daizo Kawasaki, MD, PhD; Kan Zen, MD, PhD; Kazushi Urasawa, MD, PhD; Yoshiaki Shintani, MD; Akira Miyamoto, MD; Keisuke Hirano, MD; Yusuke Miyashita, MD, PhD; Taketsugu Tsuchiya, MD, PhD; Norihiko Shinozaki, MD; Masato Nakamura, MD, PhD; Takaaki Isshiki,MD, PhD; Toshimitsu Hamasaki, MSc, PhD; Shinsuke Nanto, MD, PhD, on behalf of the STOP-IC investigators
منابع مشابه
Cilostazol reduces angiographic restenosis after endovascular therapy for femoropopliteal lesions in the Sufficient Treatment of Peripheral Intervention by Cilostazol study.
BACKGROUND It remains unclear whether cilostazol, which has been shown to improve the clinical outcomes of endovascular therapy for femoropopliteal lesions, also reduces angiographic restenosis. METHODS AND RESULTS The Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study investigated whether cilostazol reduces the 12-month angiographic restenosis rate after percutaneo...
متن کاملEfficacy of cilostazol after endovascular therapy for femoropopliteal artery disease in patients with intermittent claudication.
OBJECTIVES The purpose of this study was to investigate whether cilostazol reduces restenosis and revascularization after endovascular therapy (EVT) for femoropopliteal lesions. BACKGROUND Cilostazol improves walking distance in patients with intermittent claudication and reduces restenosis after coronary intervention, but its efficacy remains unclear after EVT for femoropopliteal disease. ...
متن کاملCilostazol increases patency and reduces adverse outcomes in percutaneous femoropopliteal revascularisation: a meta-analysis of randomised controlled trials
BACKGROUND Cilostazol is an oral antiplatelet agent currently indicated for treatment of intermittent claudication. There is evidence that cilostazol may reduce femoropopliteal restenosis after percutaneous endovascular intervention. METHODS We searched PubMed, Scopus and Cochrane databases from 1966 through September 2013 for randomised controlled trials (RCTs) evaluating the addition of cil...
متن کاملImpact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia.
BACKGROUND Cilostazol reduces restenosis and repeat revascularization after endovascular therapy (EVT) in claudicant patients with femoropopliteal lesions. However, the efficacy of cilostazol in patients with critical limb ischemia (CLI) is unclear. Therefore, we investigated the effect of cilostazol on outcomes in patients with CLI. METHODS From January 2004 to December 2009, 618 patients (3...
متن کاملCilostazol reduces target lesion revascularization after percutaneous transluminal angioplasty in the femoropopliteal artery.
BACKGROUND Although percutaneous transluminal angioplasty (PTA) is being widely used for the treatment of stenosis of peripheral arteries, the high in-stent restenosis rate (50-60%) in the femoropopliteal artery still remains an unsolved issue. Cilostazol is a unique antiplatelet drug that has vasodilatory effects and inhibits smooth muscle cell proliferation. METHODS AND RESULTS A total of 1...
متن کامل